Broad-Spectrum Vaccines:
Our first broad-spectrum vaccine is completing pre-clinical development in ferrets and pigs and entering cell line development. It was awarded a Gates Foundation Grand Challenge: End the Pandemic Threat. Featured in Netflix docuseries Pandemic: How to Prevent an Outbreak.
Broad-Spectrum Anti-Infectives:
Multidrug-resistant bacteria are reversing a century of medical progress made possible by the antibiotic revolution. Our anti-staph and anti-pseudomonas antibody programs are in pre-clinical development, supported by the Medical Technology Enterprise Consortium, the Naval Medical Research Center, the Walter Reed Army Institute of Research, and CRADAs with the United States Army Medical Research Institute of Infectious Diseases.
Broad-Spectrum Anti-Venom:
Snakebite kills 125,000 humans per year and leaves another 300,000 permanently disabled. Antivenom is the earliest antibody-based therapy, but the technology hasn’t progressed in over a century, produced in sheep or horses and being limited in breadth to certain snakes. Our broad-spectrum snake antivenom, program, made possible by 17 years of research by Director of Herpetology Tim Friede and three years of discovery and engineering by our team, is in pre-clinical development, supported by the National Institute of Health.